Covid-19-related cervical cancer treatment interruption and role of neoadjuvant chemotherapy
Covid-19相关的宫颈癌治疗中断和新辅助化疗的作用
基本信息
- 批准号:10381101
- 负责人:
- 金额:$ 13.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-19 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdverse effectsAffectAfricaBiopsyBotswanaCOVID-19COVID-19 pandemicCancer ControlCancer EtiologyCarboplatinCaringCause of DeathCessation of lifeChemotherapy and/or radiationClinicalCollaborationsComplexConflict (Psychology)CountryDataDiagnosisDiagnosticDiseaseEndoscopesEngineeringEpidemicEquipmentEvolutionFailureFundingFutureGoalsHIVHealth systemImageImmunohistochemistryInfrastructureInstitutesInterruptionInterventionLinear Accelerator Radiotherapy SystemsMalignant NeoplasmsMalignant neoplasm of cervix uteriMedicalMethodsNatural experimentNeoadjuvant TherapyOncologyOperative Surgical ProceduresOutcomePaclitaxelParticipantPathologyPatientsPoliticsPregnancyProcessPublic HealthRadiationRadiation therapyReagentResearch PersonnelResourcesRoleSARS-CoV-2 infectionServicesShockSouthern AfricaSystemTimeUniversitiesWomanbasecancer carecancer therapycare deliverycase historychemoradiationchemotherapycohortcurative treatmentsexperienceimprovedinterestmultidisciplinarypandemic diseasepreservationpreventprospectiverepairedresponsesymptom treatmenttissue processingtreatment durationtumortumor progression
项目摘要
Project Summary/Abstract
This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-
CA-21-033.
Curative therapy for locally advanced cervical cancer, the leading cause of cancer death in southern Africa,
requires chemoradiation. In nearly all countries in southern Africa, including Botswana, radiotherapy is
only available from a single center, creating substantial vulnerability. Similar to several other countries, the
radiotherapy unit in Botswana experienced prolonged downtimes due to Covid-19-related border
restrictions preventing routine service and repair. The clinical impact of delayed treatment of cervical cancer
is poorly understood and the use of `temporizing' chemotherapy to mitigate adverse effects of delays is
sparsely studied. With the goal of informing resilient and ready mitigation strategies for periods of
epidemic, armed conflict, political uprising, and environmental crises we utilize prospective data collected in
the Thabatse cancer cohort (2010 to present, n=4950) to estimate the duration of treatment delay
associated with cervical cancer stage progression and whether neoadjuvant therapy may preserve the option
for curative therapy during periods of prolonged health system disruption. Analyses will utilize the
instrumental variable methods and two natural experiments: unexpected loss of radiation therapy in
Botswana (current Covid-19 pandemic and two prior periods) and the decision by Botswana clinicians to
provide `temporizing' chemotherapy during lack of access to radiation.
项目摘要/摘要
本申请是为回应特别利益通知(NOSI)而提出的,该通知被确认为非-
CA-21-033。
当地晚期宫颈癌的根治疗法,这是南部非洲癌症死亡的主要原因,
需要化疗和放射治疗。在南部非洲的几乎所有国家,包括博茨瓦纳,放射治疗是
只能从一个中心获得,这造成了严重的漏洞。与其他几个国家类似,
博茨瓦纳放射治疗单元因新冠肺炎相关边界而停机时间延长
妨碍日常服务和维修的限制。宫颈癌延期治疗对临床的影响
人们对此知之甚少,而使用“暂时性”化疗来减轻延误的不良影响是
很少有人研究。目标是为以下时期提供有弹性的、随时可用的缓解战略
流行病、武装冲突、政治起义和环境危机,我们利用在
塔巴塞癌症队列(2010年至今,n=4950)估计治疗延迟的持续时间
与宫颈癌分期进展相关以及新辅助治疗是否可以保留这一选择
用于在长期卫生系统中断期间进行治疗。分析将利用
工具变量方法和两个自然实验:放射治疗的意外损失
博茨瓦纳(目前的新冠肺炎大流行和之前的两个时期)以及博茨瓦纳临床医生决定
在无法获得辐射的情况下提供“暂时性”化疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Scott Dryden-Peterson其他文献
Scott Dryden-Peterson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Scott Dryden-Peterson', 18)}}的其他基金
A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation
多层次干预(Potlako)可改善及时的癌症检测和治疗启动
- 批准号:
10020924 - 财政年份:2019
- 资助金额:
$ 13.6万 - 项目类别:
A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation
多层次干预(Potlako)可改善及时的癌症检测和治疗启动
- 批准号:
10242834 - 财政年份:2019
- 资助金额:
$ 13.6万 - 项目类别:
A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation
多层次干预(Potlako)可改善及时的癌症检测和治疗启动
- 批准号:
10478285 - 财政年份:2019
- 资助金额:
$ 13.6万 - 项目类别:
A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation
多层次干预(Potlako)可改善及时的癌症检测和治疗启动
- 批准号:
10696252 - 财政年份:2019
- 资助金额:
$ 13.6万 - 项目类别:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
暴露于艾滋病毒的未感染婴儿早期发病和死亡的危险因素
- 批准号:
8262976 - 财政年份:2012
- 资助金额:
$ 13.6万 - 项目类别:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
暴露于艾滋病毒的未感染婴儿早期发病和死亡的危险因素
- 批准号:
8868893 - 财政年份:2012
- 资助金额:
$ 13.6万 - 项目类别:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
暴露于艾滋病毒的未感染婴儿早期发病和死亡的危险因素
- 批准号:
8505366 - 财政年份:2012
- 资助金额:
$ 13.6万 - 项目类别:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
暴露于艾滋病毒的未感染婴儿早期发病和死亡的危险因素
- 批准号:
9086206 - 财政年份:2012
- 资助金额:
$ 13.6万 - 项目类别:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
暴露于艾滋病毒的未感染婴儿早期发病和死亡的危险因素
- 批准号:
8686729 - 财政年份:2012
- 资助金额:
$ 13.6万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 13.6万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 13.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 13.6万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 13.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 13.6万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 13.6万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 13.6万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 13.6万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 13.6万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 13.6万 - 项目类别:
Discovery Grants Program - Individual